Published in J Biol Chem on May 04, 2006
Recent advances in the development of polyamine analogues as antitumor agents. J Med Chem (2009) 1.06
Derailed estrogen signaling and breast cancer: an authentic couple. Endocr Rev (2012) 1.01
Adenosine A1 receptor, a target and regulator of estrogen receptoralpha action, mediates the proliferative effects of estradiol in breast cancer. Oncogene (2009) 0.85
Polyamine analogues: potent inducers of nucleosomal array oligomerization and inhibitors of yeast cell growth. Biochem J (2007) 0.84
Role of ornithine decarboxylase in regulation of estrogen receptor alpha expression and growth in human breast cancer cells. Breast Cancer Res Treat (2012) 0.81
Effect of polyamines and synthetic polyamine-analogues on the expression of antizyme (AtoC) and its regulatory genes. BMC Biochem (2007) 0.79
Large-scale domain motions and pyridoxal-5'-phosphate assisted radical catalysis in coenzyme B12-dependent aminomutases. Int J Mol Sci (2014) 0.77
Therapeutic evaluation of polyamine analogue drug candidates against Enterocytozoon bieneusi in a SCID mouse model. Antimicrob Agents Chemother (2009) 0.77
Biogenic and synthetic polyamines bind cationic dendrimers. PLoS One (2012) 0.75
Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression. Oncogene (2016) 0.75
OAZ1 knockdown enhances viability and inhibits ER and LHR transcriptions of granulosa cells in geese. PLoS One (2017) 0.75
Polyamines as targets for therapeutic intervention. Annu Rev Pharmacol Toxicol (1995) 3.26
Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol Endocrinol (2005) 1.67
Implications and concepts of polyamine-nucleic acid interactions. J Cell Biochem (1991) 1.41
Transcriptional regulation of estrogen receptor in breast carcinomas. Mol Cell Biol (1995) 1.27
A novel polyamine analog inhibits growth and induces apoptosis in human breast cancer cells. Clin Cancer Res (2003) 1.23
Polyamines alter sequence-specific DNA-protein interactions. Nucleic Acids Res (1995) 1.14
Protein phosphatase 2A regulates estrogen receptor alpha (ER) expression through modulation of ER mRNA stability. J Biol Chem (2005) 1.07
Molecular mechanisms of polyamine analogs in cancer cells. Anticancer Drugs (2005) 1.05
Spermine-nucleic acid interactions: a theoretical study. Biopolymers (1986) 1.04
Clinical relevance of polyamines. Crit Rev Clin Lab Sci (1983) 1.04
Novel synthetic polyamines are effective in the treatment of experimental microsporidiosis, an opportunistic AIDS-associated infection. Antimicrob Agents Chemother (2002) 1.03
Sp1 is essential for estrogen receptor alpha gene transcription. J Steroid Biochem Mol Biol (2002) 1.02
Long-chain polyamines (oligoamines) exhibit strong cytotoxicities against human prostate cancer cells. Bioorg Med Chem (2003) 0.97
A transcriptional enhancer required for the differential expression of the human estrogen receptor in breast cancers. Mol Cell Biol (1997) 0.96
Polyamine biosynthetic activity in normal and neoplastic human colorectal tissues. Cancer (1987) 0.95
High ornithine decarboxylase activity and polyamine levels in human colorectal neoplasia. Ann Surg (1986) 0.92
Regulation of polyamine analogue cytotoxicity by c-Jun in human MDA-MB-435 cancer cells. Mol Cancer Res (2004) 0.92
Regulation of estrogenic and nuclear factor kappa B functions by polyamines and their role in polyamine analog-induced apoptosis of breast cancer cells. Oncogene (2001) 0.91
Estradiol control of ornithine decarboxylase mRNA, enzyme activity, and polyamine levels in MCF-7 breast cancer cells: therapeutic implications. Breast Cancer Res Treat (1994) 0.90
Role of p53/p21(Waf1/Cip1) in the regulation of polyamine analogue-induced growth inhibition and cell death in human breast cancer cells. Cancer Biol Ther (2005) 0.88
Polyamine profiles in tumor, normal tissue of the homologous breast, blood, and urine of breast cancer sufferers. Breast Cancer Res Treat (2000) 0.86
A molecular mechanics study of spermine complexation to DNA: a new model for spermine-poly(dG-dC) binding. Proc Biol Sci (1991) 0.84
Involvement of the polyamine pathway in antiestrogen-induced growth inhibition of human breast cancer. Cancer Res (1988) 0.83
Polyamine involvement in breast cancer phenotype. In Vivo (2002) 0.80
Functional characterization of the human spermidine/spermine N(1)-acetyltransferase gene promoter. Biochim Biophys Acta (2002) 0.80
The role of polyamines in the hormonal control of breast cancer cell proliferation. Cancer Treat Res (1994) 0.80
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature (2010) 23.55
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell (2004) 21.30
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med (2003) 13.81
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 9.40
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
Estrogen carcinogenesis in breast cancer. N Engl J Med (2006) 8.17
The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther (2004) 7.82
Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med (2008) 6.54
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol (2010) 6.39
Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat Genet (2011) 5.62
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol (2014) 5.61
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst (2005) 5.55
Genome-wide SNP assay reveals structural genomic variation, extended homozygosity and cell-line induced alterations in normal individuals. Hum Mol Genet (2006) 5.50
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 5.18
Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol (2008) 5.10
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol (2011) 4.81
American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol (2006) 4.61
Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A (2011) 4.55
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol (2006) 4.55
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol (2008) 4.42
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol (2008) 4.24
The Hox genes and their roles in oncogenesis. Nat Rev Cancer (2010) 3.97
Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2009) 3.70
Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res (2008) 3.67
Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov (2007) 3.46
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol (2008) 3.40
Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst (2002) 3.34
Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell (2011) 3.07
Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med (2012) 3.03
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol (2011) 3.02
Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci U S A (2008) 2.99
The dragon strikes: lessons from the Wenchuan earthquake. Anesth Analg (2010) 2.78
Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene (2003) 2.71
HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition. Cancer Res (2006) 2.66
Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2012) 2.62
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst (2013) 2.56
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol (2010) 2.49
Modeling precision treatment of breast cancer. Genome Biol (2013) 2.42
Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell (2003) 2.38
Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res (2004) 2.29
Store-independent activation of Orai1 by SPCA2 in mammary tumors. Cell (2010) 2.29
NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol Cell (2011) 2.27
DNA methylation regulates MicroRNA expression. Cancer Biol Ther (2007) 2.21
Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2013) 2.21
Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res (2005) 2.20
The biology of breast carcinoma. Cancer (2003) 2.19
DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer (2003) 2.18
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. J Clin Oncol (2013) 2.15
Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing. Mol Cell (2008) 2.15
Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem (2005) 2.13
Implication of SSAT by gene expression and genetic variation in suicide and major depression. Arch Gen Psychiatry (2006) 2.13
Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res (2011) 2.12
Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc Natl Acad Sci U S A (2011) 2.12
Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc Natl Acad Sci U S A (2007) 2.11
P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med (2008) 2.10
The mammalian ortholog of Drosophila MOF that acetylates histone H4 lysine 16 is essential for embryogenesis and oncogenesis. Mol Cell Biol (2007) 2.07
Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res (2012) 2.07
Adjuvant endocrine therapy for breast cancer: how long is long enough? Oncology (Williston Park) (2013) 2.06
Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci U S A (2009) 2.02
Anticancer activities of novel chalcone and bis-chalcone derivatives. Bioorg Med Chem (2006) 1.96
Genetic and phenotypic diversity in breast tumor metastases. Cancer Res (2014) 1.96
Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst (2011) 1.94
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol (2007) 1.93
Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. Carcinogenesis (2007) 1.91
p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells. Cancer Biol Ther (2004) 1.90
Exercise manages fatigue during breast cancer treatment: a randomized controlled trial. Psychooncology (2005) 1.89
Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines. Cancer Biol Ther (2003) 1.88
Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin Cancer Res (2009) 1.87
Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol (2012) 1.85
Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. J Biol Chem (2005) 1.79
Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. J Med Chem (2003) 1.78
Duel nature of TGF-beta signaling: tumor suppressor vs. tumor promoter. Curr Opin Oncol (2005) 1.76
Spermine oxidation induced by Helicobacter pylori results in apoptosis and DNA damage: implications for gastric carcinogenesis. Cancer Res (2004) 1.74
Protective role of arginase in a mouse model of colitis. J Immunol (2004) 1.74
Tumor-specific changes in mtDNA content in human cancer. Int J Cancer (2005) 1.70
Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. Mol Cancer Ther (2007) 1.68
Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res (2004) 1.68
Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol Endocrinol (2005) 1.67
Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. Am J Pathol (2004) 1.66
Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation. Cancer Res (2007) 1.63
Methylated genes in breast cancer: associations with clinical and histopathological features in a familial breast cancer cohort. Cancer Biol Ther (2011) 1.62
Induction of polyamine oxidase 1 by Helicobacter pylori causes macrophage apoptosis by hydrogen peroxide release and mitochondrial membrane depolarization. J Biol Chem (2004) 1.62
RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res (2006) 1.60
The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood (2007) 1.60
Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol Cancer Res (2008) 1.59
Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res (2006) 1.58